Stockscreener 앱 받기
17.50
0.85%
-0.15
시간 외 거래:
17.50
전일 마감가:
$17.65
열려 있는:
$17.76
하루 거래량:
715.54K
Relative Volume:
0.51
시가총액:
$1.72B
수익:
-
순이익/손실:
$-44.84M
주가수익비율:
-37.23
EPS:
-0.47
순현금흐름:
$-44.23M
1주 성능:
+1.86%
1개월 성능:
+3.24%
6개월 성능:
+46.81%
1년 성능:
+76.95%
1일 변동 폭
$17.40
$17.90
1주일 범위
$17.08
$18.00
52주 변동 폭
$9.67
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
명칭
Ars Pharmaceuticals Inc
전화
858-771-9307
주소
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
SPRY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
17.50 | 1.77B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-10 | 개시 | Oppenheimer | Outperform |
| 2024-08-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 재확인 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | Raymond James | Outperform |
| 2024-03-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 개시 | William Blair | Outperform |
| 2022-12-13 | 개시 | SVB Leerink | Outperform |
모두보기
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
ARS Pharmaceuticals: Pioneering a Needle-Free Revolution in Allergy Treatment - AInvest
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results - GlobeNewswire
ARS Pharmaceuticals to discuss Q2 2025 financial results Aug 13. - AInvest
ARS Pharmaceuticals Q2 Earnings Call: Anaphylaxis Treatment Leader Reports Latest Financial Results - Stock Titan
What drives ARS Pharmaceuticals Inc. stock priceCapitalize on emerging trends for profits - Jammu Links News
How volatile is ARS Pharmaceuticals Inc. stock compared to the marketBuild a portfolio that outperforms the market - Jammu Links News
How does ARS Pharmaceuticals Inc. compare to its industry peersAchieve breakthrough financial results today - Jammu Links News
What institutional investors are buying ARS Pharmaceuticals Inc. stockMarket-beating returns - Jammu Links News
Is ARS Pharmaceuticals Inc. a growth stock or a value stockMassive portfolio appreciation - Jammu Links News
What analysts say about ARS Pharmaceuticals Inc. stockIdentify undervalued stocks poised to rally - Jammu Links News
Is ARS Pharmaceuticals Inc. stock overvalued or undervaluedBuild a portfolio that grows with the market - Jammu Links News
What makes ARS Pharmaceuticals Inc. stock price move sharplyHigh-profit capital plays - Jammu Links News
How does ARS Pharmaceuticals Inc. generate profit in a changing economyMarket-crushing stock picks - Jammu Links News
How strong is ARS Pharmaceuticals Inc. company’s balance sheetTriple-digit profit margins - Jammu Links News
Does ARS Pharmaceuticals Inc. stock perform well during market downturnsStay ahead with advanced stock screening tools - Jammu Links News
What is the risk reward ratio of investing in ARS Pharmaceuticals Inc. stockGet expert alerts on market-moving stocks - Jammu Links News
ARS Pharmaceuticals Inc. Stages Intraday Comeback — Trend ChangeConservative Long Term Growth Plans Under Review - beatles.ru
What are ARS Pharmaceuticals Inc. company’s key revenue driversDaily Trading Strategy For Smart Trading - jammulinksnews.com
What is ARS Pharmaceuticals Inc. company’s growth strategyBreakout Stocks Watchlist That Work - jammulinksnews.com
ARS Pharmaceuticals Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
Why is ARS Pharmaceuticals Inc. stock attracting strong analyst attentionDaily Trading Picks With High Returns - Jammu Links News
Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength - Yahoo Finance
Quant Models Detect Momentum Reversal in ARS Pharmaceuticals Inc.Trend Analysis for Safer Trades Gains Popularity - metal.it
ARS Pharmaceuticals Inc. Stock Approaches Key Moving AverageConservative Entry for High Return Setup Backed - beatles.ru
Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
ARS Pharmaceuticals Inc.’s Price Action Aligns with Quant SignalsTarget Return Focused Trade Insights Shared - metal.it
What institutions are buying ARS Pharmaceuticals Inc. stock nowReal Time Stock Movement Analysis Indicates Breakout - metal.it
When is ARS Pharmaceuticals Inc. stock expected to show significant growthProven strategies for superior portfolio growth - Jammu Links News
Published on: 2025-07-28 04:26:33 - jammulinksnews.com
Should I hold or sell ARS Pharmaceuticals Inc. stock in 2025Consistent double returns - Jammu Links News
ARS Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough financial growth - PrintWeekIndia
Is ARS Pharmaceuticals Inc. a good long term investmentTriple-digit return opportunities - PrintWeekIndia
Ars Pharmaceuticals Inc (SPRY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):